SCHEMBL2499152

SCHEMBL2499152

CCC(=O)Oc1c(O)cccc1NC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40
METAP1 P53582 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
CNR2 P34972 1/20 0.36
BRD9 Q9H8M2 1/20 0.36
ACHE P22303 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
NLRP3 Q96P20 1/20 0.36
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
BRD4 O60885 1/20 0.35
P2RX7 Q99572 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15414767 0.90 HSP90AA1 (0.40) HSP90AA1HSP90AB1RXFP1METAP1LMNA
SCHEMBL8741876 0.86 ACHE (0.39) KMT2ALMNAPOLBACHENLRP3
SCHEMBL15674350 0.86 HSP90AA1 (0.39) HSP90AA1HSP90AB1RXFP1METAP1LMNA
SCHEMBL6651046 0.86 RXFP1 (0.39) HSP90AA1HSP90AB1RXFP1METAP1KMT2A
SCHEMBL29019451 0.86 RXFP1 (0.41) RXFP1METAP1KMT2ALMNAPOLB
SCHEMBL28875790 0.85 RXFP1 (0.38) RXFP1METAP1KMT2ALMNAPOLB
SCHEMBL2149381 0.85 KMT2A (0.41) RXFP1KMT2ALMNAALDH1A1BRD4
SCHEMBL2078471 0.85 RXFP1 (0.38) HSP90AA1HSP90AB1RXFP1METAP1KMT2A
SCHEMBL10593240 0.84 RXFP1 (0.36) RXFP1METAP1KMT2ALMNAPOLB
SCHEMBL12475202 0.84 POLB (0.51) RXFP1KMT2ALMNAPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117946067-A Method for realizing deuteration methylation of nucleophile 南京工业大学 2024-04-30 CN disclosed
US-20240067665-A1 SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY AVIKO RADIOPHARMACEUTICALS LLC (US) 2024-02-29 US disclosed
WO-2024035871-A1 SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY AVIKO RADIOPHARMACEUTICALS, LLC (US) 2024-02-15 WO disclosed
CN-117043157-A ERAP inhibitors 里尔大学 2023-11-10 CN disclosed
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 US disclosed
US-11692008-B2 Preparation and uses of reactive oxygen species scavenger derivatives XWPharma Ltd. (KY) 2023-07-04 US disclosed
CN-110520413-B Macrocyclic broad spectrum antibiotics 阿奇克斯制药公司 2023-02-17 CN disclosed
EP-4097092-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING Protego Biopharma, Inc. (US) 2022-12-07 EP disclosed
CN-115298168-A Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding 普罗泰格生物制药公司 2022-11-04 CN disclosed
CN-114929689-A Bcl-2 inhibitors 百济神州有限公司 2022-08-19 CN disclosed
EP-3193603-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS Epizyme, Inc. (US) 2017-07-26 EP disclosed
US-20170190676-A1 Isoxazole Carboxamide Compounds Epizyme, Inc. (US) 2017-07-06 US disclosed
WO-2016040498-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS Epizyme, Inc. (US) 2016-03-17 WO disclosed
EP-2917218-A1 MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS Ensemble Therapeutics Corporation (US) 2015-09-16 EP disclosed
WO-2014074658-A1 MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-15 WO disclosed
US-8030499-B2 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-10-04 US disclosed
US-20080318923-A1 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-25 US disclosed
EP-1575911-A2 BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2005-09-21 EP disclosed
WO-2004046091-A2 BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-06-03 WO disclosed
CN-1226172-A Methods and compositions for inhibiting angiogenesis SCRIPPS RESEARCH INST (US) 1999-08-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING TTR, TTPA, TNNC1 HSP90AA1 497/4885HSP90AB1 323/4885RXFP1 4310/4885
US-20170190676-A1 Isoxazole Carboxamide Compounds SMYD3, SMYD2, SNRPD3 HSP90AA1 2675/4885HSP90AB1 3059/4885RXFP1 1554/4885
US-11692008-B2 Preparation and uses of reactive oxygen species scavenger derivatives AIFM2, GPX1, GPX4 HSP90AA1 616/4885HSP90AB1 347/4885RXFP1 968/4885
US-20080318923-A1 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle AVPR1B, AVPR1A, AVPR2 HSP90AA1 1273/4885HSP90AB1 668/4885RXFP1 253/4885
US-20240067665-A1 SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY NME2, BTD, BLVRB HSP90AA1 330/4885HSP90AB1 40/4885RXFP1 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.